November 26, 2026

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub.: Intimation regarding withdrawal of non-compliance report previously issued by National Centre for Public Health and Pharmacy, Hungary for manufacturing facility of Panacea Biotec Pharma Limited at Baddi, Himachal Pradesh

Re: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations") and in furtherance to our earlier intimation dated 5 February 2026, we are delighted to inform you that the Company's wholly owned subsidiary, Panacea Biotec Pharma Limited has received an email dated 25 November 2026 from National Centre for Public Health and Pharmacy, Hungary, ("NCPHP") regarding withdrawal of non-compliance report previously issued by NCPHP, following the re-inspection conducted at Baddi, Himachal Pradesh, India ("Baddi Facility") from 7 to 11 September 2026.

NCPHP is not able to issue a new GMP certificate in Eudra for the next few days, as their organisation has undergone a restructuring and has been given a new name, which has not yet been implemented in the Eudra system. However, the EU GMP Certificate once issued shall be valid for a period of 3 (three) years from the date of inspection.

Following the receipt of confirmation of EU GMP compliance, Panacea Biotec Pharma Limited will now commence supplies to Germany, European Union and other affected markets.

This achievement reaffirms Panacea Biotec Pharma Limited's commitment to maintaining the highest standards of quality, safety and regulatory compliance across its operations. It reflects Panacea Biotec Pharma Limited's continued focus on operational excellence and adherence to the stringent requirements and standards prescribed by global regulatory authorities.

The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, and other circulars as may be applicable from time to time, is annexed herewith as **Annexure A.**

This is for your kind information and record please.

Thanking you,
Sincerely yours,
For **Panacea Biotec Limited**

ANKIT JAIN Digitally signed by ANKIT JAIN Date: 2026.11.26 12:50:03 +05'30'

Ankit Jain
General Manager – Legal & Company Secretary

Encl. as above

Annexure – A

Details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations") read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026

#	Particulars	Details
a.	Name of the regulatory or licensing authority	National Centre for Public Health and Pharmacy, Hungary ("NCPHP")
b.	Brief details of the approval / license obtained / withdrawn / surrendered	Withdrawal of non-compliance report previously issued by NCPHP for manufacturing facility of Panacea Biotec Pharma Limited at Baddi, Himachal Pradesh, following the re-inspection conducted from 7 to 11 September 2026.
c.	Impact / relevance of such approval / license to the listed entity	Panacea Biotec Pharma Limited will now commence supplies to Germany, European Union and other affected markets.
d.	Withdrawal / cancellation or suspension of licence/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any	Not Applicable
e.	Period for which such approval / license is/was valid	NCPHP is not able to issue a new GMP certificate in Eudra for the next few days, as their organisation has undergone a restructuring and has been given a new name, which has not yet been implemented in the Eudra system. However, the EU GMP Certificate once issued shall be valid for a period of 3 (three) years from the date of inspection.
f.	Subsequently, the listed entity shall inform the stock exchange(s), the actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval	Not Applicable

This is for your kind information and record please.

Thanking you,
Sincerely yours,
For **Panacea Biotec Limited**

ANKIT JAIN
Digitally signed by ANKIT JAIN
Date: 2026.11.26 12:50:30 +05'30'

Ankit Jain
General Manager – Legal & Company Secretary